Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$1.60M

FY 2025 · Annual

Investing Cash Flow

$18.13M

FY 2025 · Annual

Financing Cash Flow

$12.06M

FY 2025 · Annual

-85.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.56M)(41.54M)(46.05M)(105.51M)83.23M
Depreciation & Amortization257K944K1.01M6.39M4.05M
Deferred Income Tax16.2M0015.37M3.45M
Stock-Based Compensation2.44M4.29M5.95M14.91M12.63M
Change in Working Capital(357K)(406K)5.88M(6.64M)(26.51M)
Accounts Receivables1.05M(6.77M)(9.08M)6.87M(11.98M)
Inventory0147K206K(8.87M)(1.31M)
Accounts Payables(1.11M)3.13M11.13M(3.6M)(15.59M)
Other Working Capital(295K)3.09M3.63M(1.04M)2.36M
Other Non-Cash Items460K17.99M(329K)5.82M(78.45M)
Operating Cash Flow10.44M(18.72M)(33.54M)(69.67M)(1.6M)
Capital Expenditures(102K)(93K)(296K)0(835K)
Acquisitions (Net)0(14.09M)(30.4M)00
Purchases of Investments(15.42M)(22.54M)(45.81M)(41.16M)(309.99M)
Sales of Investments036.63M59.12M25M328.5M
Other Investing Activities0(36.63M)0(6M)448K
Investing Cash Flow(15.52M)(36.72M)(17.39M)(22.16M)18.13M
Debt Repayment(38.1M)12.78M25.59M16.29M0
Common Stock Issued49.29M324K6.32M64.52M12.44M
Common Stock Repurchased(2.81M)(4.72M)(3.45M)00
Dividends Paid00000
Other Financing Activities104.74M291K6.32M1.3M(372K)
Financing Cash Flow113.11M8.35M28.46M82.11M12.06M
Effect of Forex Changes0204K44K454K28K
Net Change in Cash108.02M(46.88M)(22.42M)(9.26M)28.62M
Free Cash Flow10.34M(18.81M)(33.83M)(69.67M)(2.43M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$83.2M
+ D&A$4.1M
+ Stock-Based Comp$12.6M
+ Deferred Tax$3.4M
- Working Capital-$26.5M
- Other Non-Cash-$78.5M
= Operating Cash Flow-$1.6M
- Capex-$835.0K
= Free Cash Flow-$2.4M

Analysis

FY2025 free cash flow is -$2.4M. FCF conversion is -2.9% of net income. Operating cash flow was -$1.6M, with capex of -$835.0K. The largest bridge item is Other Non-Cash at -$78.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 5, 2026
8-KCurrent reportNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipOct 13, 2026
4Statement of changes in beneficial ownershipAug 17, 2026

Does ZVRA generate free cash flow?

Zevra Therapeutics, Inc. (ZVRA) generated -$2.43M of free cash flow in fiscal 2025.

How much operating cash flow does ZVRA produce?

Operating cash flow was -$1.60M, before capital expenditures of $835,000.00.